Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph not_applicable
1
50%
Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_2

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
recruitingnot_applicable

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

NCT07125729

Clinical Trials (2)

Showing 2 of 2 trials
NCT05987241Phase 2

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Recruiting
NCT07125729Not Applicable

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2